HD Insights™

HD INSIGHTS TM Meet the Company VITAL SIGNS NAME: Prana Biotechnology HEADQUARTERS: Parkville, Victoria, Australia STOCK PRICE AS OF 10/05/11: $1.59 52 WEEK RANGE: $1.13-4.50 MARKET CAPITALIZATION AS OF 10/05/11: $42.4 million EMPLOYEES: Approximately 10! Geoffrey Kempler, CEO Prana Biotechnology Prana Biotechnology's research is driven by the hypothesis that metal protein attenuating compounds bind transition metals and prevent oligomerization of amyloid proteins in Alzheimer disease and of the huntingtin protein in Huntington disease. Prana Biotechnology CEO Geoffrey Kempler sat down with HD InsightsTM at the World Congress on Huntington's Disease to discuss Prana's research in neurological disease modification. Excerpts from the discussion are below. INSIGHTS: Could you tell us a little bit about Prana? KEMPLER: Prana began in 1997 as a private company through some seed capital financing that came in from myself and a friend of mine, Barry Lieberman. We became interested in some work that was happening at Harvard Mass General. The work was on the amyloid protein and the role of metals in facilitating the aggregation of this protein into oligomers and plaques. What we were doing was considered heretical because we were really the first group to start to understand the metal binding sites on these proteins, and that these metals were driving the aggregation of the proteins. We supported our research very privately. We had a peripheral concept growing that was already available in the market and matched our scientific theory. There, we could do that concept work. By us understanding the mechanism that's behind protein aggregation, we've been able to drive an enormous amount of academic publications through our support laboratories at Harvard, here in Melbourne at the Mental Health Research Institute and the University of Melbourne, and at some other collaborations we've had in various parts of the world. INSIGHTS: It makes a lot of sense that a company like yours might be interested in Alzheimer disease, which has a very large market. Tell us why you are interested in Huntington disease. KEMPLER: You imagine that companies always look at market size and market opportunity, and that's true. I don't want in any way diminish that as a focus. We know that cognition is one of the key areas of deficit in Huntington disease patients. We know that it's a major aspect of Alzheimer disease, but we also know that there's some normal cognitive decline that comes just with the aging process even if you don't have either of these diseases. HD InsightsTM, Vol. 1 Copyright © Huntington Study Group 2011. All rights reserved. 9

• Cover